Mepyramine对肝脏疾病肝微粒体膜流动性的影响

目的:探讨Mepyramine对肝脏疾病肝微粒体膜流动性的影响.方法:以1,6-diphenyl-1,3,5-hexatriene(DPH)作为荧光探剂,应用荧光偏振技术研究大鼠急性肝炎、大鼠肝硬化肝微粒体膜流动性(LMMF)的变化,并在体外实验观察mepyramine(MPR)对LMMF的影响.结果:①LMMF在大鼠发生急性肝炎时升高,与对照组相比有显著性差异(P＜0.o1),而大鼠发生肝硬化时降低,与对照组相比有显著性差异(P＜0.05).②10-4mol/L MPR可使正常大鼠、大鼠肝硬化及人体肝癌组织LMMF升高(P分别小于0.01,0.01,0.05).结论:肝病时LMMF出现异常;MPR可以升高LMMF,其机制可能与阻断抗组胺药敏感性细胞色素P450(HP-450)有关.     

Effect of Complexation with Hydroxylpropyl-β-Cyclodextrin on Solubility, Dissolution Rate and Chemical Stability of Prostaglandin E1

Aim To study the effect of complexation with hydroxylpmpyl-β-cycledextrin (HP-β-CD) on the solubility, dissolution rate and chemical stability of pmstaglandin E1 (PGE1), thereby providing a basis for preparing a stable solid or aqueous preparation of PGF1 formulated with HP-β-CD. Methods The effect of HP-β-CD on the solubility of PGF1 was studied by phase solubility method. The formation of inclusion complexes of PGE1 with HP-β-CD in the aqueous solution was confirmed by UV spectra, circular dichroism spectroscopy, and that in the solid state by IR spectra and X-ray diffractometry. An solid inclusion complex of PGF1 with HP-β-CD was prepared by lyophilization. The dissolution rate and stability of the inclusion complex were determined and compared with those of PGE1 alone. Meanwhile, the stability of PGF1 aqueous solutions in the presence of HP-β-CD was studied under different pH conditions. Results The solubility of PGF1 increased linearly with increasing HP-β-CD concentration in various pH buffered solutions, showing typical AL-type phase solubility diagrams. The stability and dissolution rate of the solid inclusion complex of PGE1 were significantly increased, compared with those of pure PGE1 . The stability of PGEI in HP-β-CD solutions was also obviously improved under acidic and basic conditions, but the stabilizing effect was absent under neutral conditions. Conclulsions The solubility, dissolution rate and chemical stability of PGE1 are markedly improved by complexation with HP-β-CD. It is quite possible to prepare a stable PGE1 inclusion complex-containing solid dosage forms, but almost impossible to obtain a stable aqueous preparation of PGE1 formulated with HP-β-CD.     

乳化溶剂扩散法制备罗红霉素肠溶微球及影响因素考察

目的罗红霉素肠溶微球的制备及影响因素考察。方法应用肠溶高分子材料 ,采用乳化溶剂扩散法一步制备罗红霉素肠溶微球。对影响微球形态、粒度分布、收率及其在 0 . 1mol·L-1盐酸溶液和 pH 6 8磷酸盐缓冲溶液中累积释放度的处方因素、制备条件和溶剂系统进行了考察。应用X 射线粉末衍射实验考察了药物在微球中的分散状态。结果制备的微球外观圆整。微球粒径随着搅拌转速的增加而减小。微球收率随架桥剂用量减少 ,良溶剂用量增加而增加 ;并且受到不良溶剂中乳化剂种类的影响。药物在 0 . 1mol·L-1盐酸溶液中的释放速率随肠溶材料HP- 5 5用量增加显著降低。当HP- 5 5与药物质量比大于 5时 ,药物在 0 . 1mol·L-1盐酸溶液中释放小于 5 % (w) ,同时在pH 6 . 8磷酸盐缓冲溶液中可迅速释放。X- 射线粉末衍射结果显示 ,微球中药物已被高度分散 ,形成固体分散体。结论乳化溶剂扩散法适用于制备具有固体分散体结构的肠溶微球。     

响应曲面法优化姜黄素包合物的制备

目的:探讨姜黄素羟丙基β-环糊精包合物curcumin HP-β-cyclodextrin inclusion complex,CUR-HP-β-CD)的包合工艺。方法:以包合物的产率为考查指标,考查温度、搅拌时间、乙醇浓度对产率的影响。采用响应曲面法对实验进行设计,采用饱和水溶液法制备包合物,通过紫外扫描和差示扫描量热法对包合物进行验证。结果:制备姜黄素羟丙基β-环糊精包合物的最佳条件为乙醇浓度为40%,饱和温度50℃,反应时间4 h。紫外扫描和差示扫描量热法证明了所得产物为包合物;结论:本工艺适用于制备姜黄素羟丙基β-环糊精包合物。     

Cyclodextrin Reduces Intravenous Toxicity of a Model Compound

Solubilization of new chemical entities for toxicity assessment must use excipients that do not negatively impact drug pharmacokinetics and toxicology. In this study, we investigated the tolerability of a model freebase compound, GDC-0152, solubilized by pH adjustment with succinic acid and complexation with hydroxypropyl-β-cyclodextrin (HP-β-CD) to enable intravenous use. Solubility, critical micelle concentration, and association constant with HP-β-CD were determined. Blood compatibility and potential for hemolysis were assessed in vitro. Local tolerability was assessed after intravenous and subcutaneous injections in rats. A pharmacokinetic study was conducted in rats after intravenous bolus administration.GDC-0152 exhibited pH-dependent solubility that was influenced by self-association. The presence of succinic acid increased solubility in a concentration-dependent manner. HP-β-CD alone also increased solubility, but the extent of solubility enhancement was significantly lower than succinic acid alone. Inclusion of HP-β-CD in the solution of GDC-0152 improved blood compatibility, reduced hemolytic potential by ～20-fold in vitro, and increased the maximum tolerated dose to 80 mg/kg.     

氟尿嘧啶-羟丙基-β-环糊精包合物温敏凝胶生物黏附力及溶出度研究

目的：考察不同生物黏附材料对氟尿嘧啶-羟丙基-β-环糊精包合物温敏凝胶剂粘附性及溶出度的影响。方法：以羟丙基甲基纤维素（HPMC）、海藻酸钠、透明质酸钠、卡波姆、聚卡波菲为生物黏附材料制备氟尿嘧啶-羟丙基-β-环糊精包合物温敏凝胶剂,测定各处方的黏附力,并在溶出介质p H 7.2磷酸盐缓冲液中,用透析袋法进行体外释药试验。结果：以0.2%聚卡波菲为生物黏附材料的处方黏附力为32.3 g·ml^-1,药物释放时间延长至8 h,采用不同的生物黏附材料对制剂溶出行为没有显著影响。结论：以0.2%聚卡波菲为生物黏附材料,制备氟尿嘧啶-羟丙基-β-环糊精包合物温敏凝胶剂黏附力高,且具有良好的缓释效果。     

西洛他唑与羟丙基-β-环糊精包合的热力学研究

目的：研究西洛他唑（CLTZ）与羟丙基-β-环糊精（HP-β-CD）在混合溶液中的包合作用及其包合过程中热力学参数的变化。方法：运用 RP-HPLC 法测定 CLTZ 与 HP-β-CD 在混合溶液中包合的平衡常数（Kf）,计算与分析其热力学的参数变化。结果：CLTZ 与 HP-β-CD 可形成 mol∶mol（1∶1）包合物,包合过程可自发进行（ΔG＜0）,且为放热反应（ΔH＜0）,也是熵减过程（ΔS＜0）。结论：CLTZ 与 HP-β-CD 可形成 mol∶mol（1∶1）可溶性包合物,从而增加其溶解度,且较低的温度有利于包合物的形成和稳定。     

三种注射用新辅料对Beagle犬类过敏及过敏反应研究

目的研究3种注射用新辅料乙交酯-丙交酯共聚物（PLGA）、乙二醇单甲醚-聚乳酸嵌段共聚物（mPEG-PDLLA）和羟丙基-β-环糊精（HP-β-CD）能否引起Beagle犬产生类过敏或过敏反应,为临床研究和应用提供依据。方法使用Beagle犬于1、3、5d致敏共3次,末次致敏后第14d激发。观察给药后反应症状,检测常规血液学指标、血浆中组胺、IgE、IgG和IgM含量。结果上述各项指标在首次给药后和激发日激发后均未见明显异常改变。结论 PLGA、mPEG-PDLLA和HP-β-CD在本实验剂量下不能引起Beagle犬产生类过敏或过敏反应。     

溶液搅拌法制备大豆苷元-羟丙基-β-环糊精包合物的研究

目的制备大豆苷元-羟丙基-β-环糊精包合物并考察其表观性质。方法采用正交试验优化大豆苷元-羟丙基-β-环糊精(HP-β-CD)包合物的制备工艺,通过电镜扫描、红外、X射线衍射考察包合物表观性质,并测定了包合物的粒径分布。结果最佳制备工艺为∶HP-β-CD和大豆苷元摩尔比1∶1、温度控制为45℃、包合时间为4 h、HP-β-CD浓度为10%,形成的包合物表观形态好,粒径分布均匀。结论此工艺适合于大豆苷元-HP-β-CD包合物的制备。     

羟丙基-β-环糊精对兰索拉唑的增溶作用及其包合物的制备

目的研究羟丙基-β-环糊精(HP--βCD)对难溶性药物兰索拉唑(LPZ)的包合作用。方法绘制相溶解度图,考察pH变化、碳酸氢钠的加入对LPZ的增溶作用。采用共蒸发法(CE)和喷雾干燥法(SD)按照LPZ∶HP--βCD量比为1∶1或1.0∶1.5的比例制备LPZ/HP--βCD包合物,测定其溶出度,并利用差示扫描量热法(DSC)和傅立叶红外光谱法(FTIR)对SD法制备的包合物进行结构表征。结果在pH 11条件下,HP-β-CD与NaHCO3对LPZ的协同增溶效果最好。体外溶出实验表明:CE法和SD法制备的包合物溶出均优于LPZ与HP-β-CD的物理混合物。结论HP--βCD能明显提高LPZ的溶解度和溶出度。